MCC protocol: Clinical Trials

5 trials of MCC protocol, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed. 3 Phase 4, 2 Not applicable.

By phase and status

PhaseTrialsStatus
Phase 43Completed 3
Not applicable2Completed 2

Follow MCC protocol: new trials by email Literature Review of MCC protocol trials Research Report on MCC protocol

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Effects of Carboxymethylcellulose Artificial Tears on the Eye Microbiome
Carboxymethylcellulose (CMC) Artificial Tears, Preservative-free, CMC-free Artificial Tears (control) - Dry Eye Syndromes
Phase 4CompletedUniversity of Florida802022-04-222023-04-20
Evaluating HA 0.15% Compared With Cyclosporine 0.05%, and Efficacy of Combination Therapy in Dry Eye Disease Patients
TJO-018 (HA 0.15%), Cyclosporine Ophthalmic Emulsion 0.05% standard therapy (CMC 0.5% add), TJO-018 (HA 0.15%) + Cyclosporine Ophthalmic Emulsion 0.05% - Dry Eye, Dry Eye Syndromes
Phase 4CompletedTaejoon Pharmaceutical Co., Ltd.4382019-11-122022-06-08
Opioid Treatment and Recovery Through a Safe Pain Management Program
Electronic medical recorded clinical decision support [EMR CDS], Stepped opioid collaborative care model [CCM] - Depression, Opioid Use
Not applicableCompletedOchsner Health System4902019-04-012026-04-06
Strength and Function Following Total Hip Arthroplasty
Multi-Component Rehabilitation (CMC), Control (CON) - Total Hip Arthroplasty
Not applicableCompletedUniversity of Colorado, Denver682012-09-012016-07-11
Comparative Study of 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxychlorocomplex (PURITE™) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye
0.5% carboxymethylcellulose (CMC) with purite and CMC alone - Dry Eye Syndromes
Phase 4CompletedChulalongkorn University1002004-02-012015-06-03

Conditions studied

Dry Eye Syndromes (3)  ·  Anxiety Disorders (1)  ·  Chronic Pain (1)  ·  Depression (1)  ·  Osteoarthritis, Hip (1)

Sponsors

Chulalongkorn University (1)  ·  Ochsner Health System (1)  ·  Taejoon Pharmaceutical Co., Ltd. (1)  ·  University of Colorado, Denver (1)  ·  University of Florida (1)

Countries

United States (3)  ·  South Korea (1)  ·  Thailand (1)

Top investigators

Jennifer Stevens-Lapsley, PT,PhD (1)  ·  Nipaporn Maneerat, MD (1)  ·  Pitipong Suramethakul, MD (1)  ·  Vilavun Puangsricharern, MD (1)  ·  Yujia Zhou (1)

Results publications

PMID 37555738, PMID 39095571, PMID 41838978